Alembic Pharma Q1 FY26 Earnings Profit Rises 14% YoY; Revenue Up 9.5% Backed by Global Growth

Alembic Pharmaceuticals posted a consolidated net profit of ₹156.63 crore for the quarter ended June 2025, marking a 14.18% increase from ₹134.54 crore in Q1FY25. Revenue rose 9.54% YoY to ₹1,710.72 crore, showing healthy growth across domestic and international markets.

Alembic Pharma Q1 FY26 Earnings: Profitability and Margins

The company’s Profit Before Tax (PBT) stood at ₹190.10 crore, up 21% YoY. EBITDA grew 20% to ₹288 crore, with the EBITDA margin at 17%, reflecting better operational efficiency.

India Business and Speciality Segments

The India Branded Business reported 5% YoY growth, contributing ₹599 crore in revenue. Strong momentum was seen in speciality therapies like gynaecology, cardiology, anti-diabetic, ophthalmology, and animal health. Alembic also introduced 3 new products during the quarter.

Global Operations Drive Growth

• US Generics business rose 13% YoY to ₹523 crore, with four new product launches.
• Ex-US Generics surged 21% to ₹328 crore, backed by global expansion.
• The company received six ANDA approvals, taking the total to 223.
• API segment grew modestly by 1%, earning ₹261 crore.

Pranav Amin, MD of Alembic Pharma, said the quarter reflected strong execution across geographies. Growth in US and RoW markets, cost controls, and better utilisation of manufacturing plants are expected to boost profitability going forward.

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is a vertically integrated pharma firm involved in R&D, manufacturing, and global marketing of generic medicines. Its facilities are approved by top regulators like the USFDA.

Read More: SBI, Bank Of Baroda, PNB and Other PSBs with the Highest Number of Vacancies in 2025!

Alembic Pharmaceuticals Share Price Movement

As of 9:24 AM on August 6, 2025, Alembic Pharmaceuticals share price (NSE: APLLTD) was trading at ₹938.25, down 0.87% for the day. The stock opened at ₹950.00 and moved between a high of ₹955.50 and a low of ₹935.00. The company’s market capitalisation stood at ₹18,590 crore, with a P/E ratio of 31.61 and a dividend yield of 1.17%. Its 52-week high and low are ₹1,303.90 and ₹725.20, respectively, and the latest quarterly dividend amount is ₹2.74.

Conclusion

Alembic Pharma has kicked off FY26 on a strong note with consistent growth in profits and revenues. Its robust global performance and speciality focus set the stage for sustained expansion, despite ongoing pricing pressure in the US market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.